Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.
Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, van Werkhoven E, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM. Henricks LM, et al. Among authors: dezentje vo. Eur J Cancer. 2019 Jan;107:60-67. doi: 10.1016/j.ejca.2018.11.010. Epub 2018 Dec 11. Eur J Cancer. 2019. PMID: 30544060
Emphasizing the value of phenotyping in patients receiving tamoxifen.
Opdam FL, Dezentje VO, den Hartigh J, Guchelaar HJ, Gelderblom H. Opdam FL, et al. Among authors: dezentje vo. J Clin Oncol. 2012 Feb 1;30(4):464; author reply 465. doi: 10.1200/JCO.2011.38.8892. Epub 2011 Dec 19. J Clin Oncol. 2012. PMID: 22184383 No abstract available.
The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels.
Opdam FL, Dezentje VO, den Hartigh J, Modak AS, Vree R, Batman E, Smorenburg CH, Nortier JW, Gelderblom H, Guchelaar HJ. Opdam FL, et al. Among authors: dezentje vo. Cancer Chemother Pharmacol. 2013 Mar;71(3):593-601. doi: 10.1007/s00280-012-2034-4. Epub 2012 Dec 11. Cancer Chemother Pharmacol. 2013. PMID: 23228987
CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
Dezentjé VO, van Schaik RH, Vletter-Bogaartz JM, van der Straaten T, Wessels JA, Kranenbarg EM, Berns EM, Seynaeve C, Putter H, van de Velde CJ, Nortier JW, Gelderblom H, Guchelaar HJ. Dezentjé VO, et al. Breast Cancer Res Treat. 2013 Jul;140(2):363-73. doi: 10.1007/s10549-013-2619-6. Epub 2013 Jul 11. Breast Cancer Res Treat. 2013. PMID: 23842856 Clinical Trial.
CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
Dezentjé VO, Gelderblom H, Van Schaik RH, Vletter-Bogaartz JM, Van der Straaten T, Wessels JA, Kranenbarg EM, Berns EM, Seynaeve C, Putter H, Van de Velde CJ, Nortier JW, Guchelaar HJ. Dezentjé VO, et al. Breast Cancer Res Treat. 2014 Jan;143(1):171-9. doi: 10.1007/s10549-013-2777-6. Epub 2013 Nov 22. Breast Cancer Res Treat. 2014. PMID: 24265036
The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity.
Welzen ME, Dezentjé VO, van Schaik RH, Colbers AP, Guchelaar HJ, van Erp NP, den Hartigh J, Burger DM, van Laarhoven HW. Welzen ME, et al. Among authors: dezentje vo. Ther Drug Monit. 2015 Aug;37(4):501-7. doi: 10.1097/FTD.0000000000000195. Ther Drug Monit. 2015. PMID: 26192892 Clinical Trial.
49 results